

## REMARKS

In the Office Action of September 21, 2007, the Examiner objected to the specification for not including SEQ ID numbers on pages 4, 14 and 25. With the present amendments to the specification these Sequence ID numbers are included.

Claims 9-10 stand rejected under 35 U.S.C. § 112, second paragraph, for being indefinite for lack of antecedent basis for "the vaccine."

With the present amendments claim 9 now refers to immunogens of other pathogens and claim 10 refers to the immunogenic composition and not a vaccine. It is believed that these amendments are in accord with the previous amendments submitted in response to the Office Action of March 22, 2007.

Claims 1, 2 and 7 stand rejected under 35 U.S.C. § 102(b) for being anticipated by Vakharia *et al.* (US 6017759). Table 5 as referred to for showing the Intervet Prime Vac binding with monoclonal antibodies 63, 69 and 67, thereby meeting the requirements of claims 1 and 2. It is identified as a vaccine virus, thereby meeting the requirements of claim 7.

Claims 8-10 stand rejected under 35 U.S.C. § 103(a) for being obvious over Vakharia *et al.* because Vakharia *et al.* are said to disclose a vaccine strain.

With the present amendments it is respectfully submitted all claims now contain the limitations of claim 3 and are therefore in condition for allowance. The Examiner observed that claims 3-6 were objected to for being dependent on a rejected base claim but would be allowable if rewritten in independent form including all the limitations of the base claim and any of the intervening claims.

In view of the above it is believed that claims 3-20 are in condition for allowance. Favorable action is solicited.


Should the Examiner consider that a conference would be helpful in advancing the prosecution of this application, she is invited to telephone the Applicants' attorney at the number below.

USSN: 10/809,176  
Attorney Docket: 2003.002 US  
Response to Office Action of September 21, 2007

Applicants do not believe that any other fee is due in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **02-2334**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **02-2334**.

Applicants submit that this application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



William M. Blackstone, PTO Reg. No: 29,772  
Chief Patent Counsel  
Patent Department  
Intervet Inc.  
P.O. Box 318  
29160 Intervet Lane  
Millsboro, DE 19966  
(302) 934-4317 (tel)  
(302) 934-4305 (fax)